The Role of High-Quality APIs in Breast Cancer Treatment: Advancing Personalized Approaches and Regulatory Frameworks
Kolade Adeyemo *
Youngstown State University, United States.
*Author to whom correspondence should be addressed.
Abstract
Aim: To discuss the development and manufacturing of high-quality active pharmaceutical ingredients for breast cancer treatment focusing on how their efficiencies can be improved through personalized medicine and regulatory excellence.
Problem Statement: Breast cancer is known as the most prominent global menace among women and a foremost source of cancer-related mortality. Orthodox treatments, such as chemotherapy, hormone therapy, small-molecule targeted therapy, radiotherapy and surgery usually fall short of handling the heterogeneity and complexity of definite breast cancer subdivisions causing metastatic progression and drug resistance.
Significance of Study: Thus, it is imperative to investigate on innovative therapeutic agents and targets to ameliorate the hardship accorded with breast cancer treatment. Enhancing the efficiencies of developed and manufactured high-quality active pharmaceutical ingredients in treating breast cancer via personalized medicine and regulatory excellence is a promising method to tackle this menace.
Methodology: This review article was compiled by conducting a systematic review of peer-reviewed literature to get updated published articles that are related to breast cancer treatment and development of active pharmaceutical ingredients.
Discussion: This review article discusses the fundamental principles behind the progression of breast cancer in women. An overview of breast cancer with regarding its stages of development, subdivisions, analysis of incidence and treatment strategies is presented within. The attributes of personalized medicine were stated to include personalized, preventative, predictive and participatory. Consideration was given to the application of genomic technique to drug development.
Conclusion: In conclusion, the development and manufacturing of high-quality APIs for breast cancer treatment should be encouraged and its efficiency should be enhanced via personalized medicine and regulatory excellence to ameliorate the menace of breast cancer globally.
Keywords: Breast cancer, personalized medicine, active pharmaceutical ingredients, regulatory excellence, chemotherapy